Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
Completed · Phase 1, Phase 2 · NCT05992935
Conditions: Norovirus Acute Gastroenteritis
At a glance
- Research payments reported, 2025
- $3.3M
- U.S. investigators named
- 14
- Sites paid
- 25
- Planned or actual enrollment
- 1,407
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1403 (biological), mRNA-1405 (biological), Placebo (biological)
- Dates
- Started 2023-08-25; completion 2026-10-07
- Results posted
- Not yet
The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants (18 to 80 years of age).
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $3.3M in research payments for this study in 2025 (435 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Todd Bertoch, M.D. Anesthesiology · Prescott, AZ
- Apinya B. Vutikullird, D.O. Family Medicine · Cypress, CA
- Clint Flanagan, MD Family Medicine · Dacono, CO
- Nelia E. Sanchez-crespo, M.D. Internal Medicine · Hollywood, FL
- Marshall L. Nash, M.D. Neurology · Decatur, GA
- Mark A. Turner, MD Family Medicine · Meridian, ID
- Daniel H. Brune, M.D. Family Medicine · Creve Coeur, IL
- Carlos A. Fierro, MD General Practice · Kansas City, KS
- Shishir K. Khetan, MD Internal Medicine · Rockville, MD
- David J. Ensz, M.D. Family Medicine · South Sioux City, NE
- Charles Harper JR., MD Internal Medicine · Norfolk, NE
- Frederick C. Raiser III, DO Emergency Medicine · Omaha, NE
- Matthew G. Davis, MD Family Medicine · Rochester, NY
- Hareshkumar D. Boghara, M.D. Family Medicine · Desoto, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $1.6M
- Rochester Clinical Research LLC $311,759
- Epic Medical Research LLC $245,034
- Tekton Research LLC $232,806
- Sandhill Research LLC $223,937
- Ark Clinical Research LLC $205,965
- Johnson County Clintrials LLC $191,521
- Synexus Clinical Research US Inc $108,356
- Research Centers of America LLC $87,224
- Jbr Clinical Research LLC $83,877
- Clinical Biosafety Services LLC $1,500
- Rochester Clinical Research $136
- Johnson County Clin-Trials (jcct) $136
- Research Centers of America $136
- Accel Research Sites Network - Neurostudies $100
- Velocity Clinical Research-Norfolk $86
- Rockville Internal Medicine Group $86
- Epic Medical Research, LLC $86
- Tekton Research, Inc - Longmont Center $86
- Velocity Clinical Research-Omaha $86
- Velocity Clin Research-Sioux City $86
- Jbr Clinical Research $86
- Optimal Research $86
- Ark Clinical Research, LLC $86
- Velocity Clinical Research - Boise $86
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.